Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Sofant and Inmarsat announce joint development

24 May 2023 07:00

RNS Number : 4074A
NetScientific PLC
24 May 2023
 

Reach: 24 May 2023

NetScientific plc

("NetScientific" or the "Company")

Sofant Technologies and Inmarsat Government to develop Phased Array Antenna for Aircraft

NetScientific Plc (AIM: NSCI), investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies, reports that its portfolio company, Sofant Technologies ("Sofant"), a leading innovator in advanced antenna technologies, and Inmarsat Government ("Inmarsat"), the leading provider of secure, global, mission-critical telecommunications to the US Government, have today announced a joint development aimed at revolutionising the communication capabilities of aircraft.

Together, Sofant and Inmarsat will collaborate on a state-of-the-art phased array antenna designed to enhance connectivity, reliability, and performance in airborne operations.

The collaboration will combine their respective expertise to develop an innovative solution that addresses the Government airborne users' growing demand for efficient, low-profile communication systems.

The new phased array antenna will leverage Sofant's core technology to produce a compact, lightweight, and low-power terminal, which will enable reliable, seamless high-speed global coverage on a wider range of aircraft through Inmarsat's Global Xpress (GX) network, the world's first and only high-throughput commercial wideband network available worldwide. This includes seamless switching on the GX commercial network's global service beams and Inmarsat's high-capacity, global military Ka-band (Mil Ka) network's steerable beams.

David Wither, CEO, Sofant Technologies, said:

"We are thrilled to partner with Inmarsat Government on this development program. By leveraging our leading-edge antenna technology, we aim to deliver a transformative solution that will redefine communication capabilities for airborne platforms. This collaboration aligns with our vision of revolutionizing connectivity in the aerospace industry and beyond. We are confident that our joint efforts will yield exceptional results."

Steve Gizinski, President, Inmarsat Government, said:

"We are dedicated to providing cutting-edge communication solutions that empower our customers to excel in their missions. Collaborating with Sofant Technologies allows us to push the boundaries of innovation further, and together, we will develop a phased array antenna that sets new industry standards. This collaboration represents a significant step forward in meeting the Government's growing demand for secure and reliable connectivity worldwide."

Dr Ilian Iliev, CEO of NetScientific, added:

"We gained exposure to the Sofant investment through our acquisition of EMV Capital and its portfolio, and since then NetScientific has supported investments through our capital light investment approach, combining direct and advised stakes. A key feature of our deep tech investment model is to encourage portfolio companies to work closely with global OEMs as a capital efficient way of growth, and to internationalise early. Hence, we are delighted with today's announcement, which is a significant milestone for Sofant. The development collaboration between Inmarsat and Sofant underscores their commitment to driving advancements in airborne communication technology."

-Ends- 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6867

Email: nsci@belvederepr.com

 

About NetScientific

NetScientific plc (AIM: NSCI) is an investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASEUFMDEDSEFI
Date   Source Headline
30th Nov 20201:56 pmRNSEMV Capital leads a £1.28m investment in SageTech
19th Nov 20207:00 amRNSProAxsis appoints DiaPharma as distributor
11th Nov 20202:10 pmRNSPDS updates on Versamune based COVID-19 vaccine
10th Nov 202012:47 pmRNSPDS Biotech Initiates VERSATILE-002 Phase 2 Trial
27th Oct 20209:46 amRNSPDS Announces Initiation of PDS0101 Phase 2 Trial
16th Oct 20207:00 amRNSNetScientific acquires 100% of portfolio company
30th Sep 20209:08 amRNSDirector/PDMR Shareholding
30th Sep 20209:07 amRNSHolding(s) in Company
30th Sep 20208:58 amRNSHolding(s) in Company
25th Sep 202012:37 pmRNSGrant of Options to Director
24th Sep 20207:00 amRNSInterim Results
2nd Sep 20207:00 amRNSHolding(s) in Company
2nd Sep 20207:00 amRNSHolding(s) in Company
24th Aug 202011:28 amRNSResult of General Meeting
21st Aug 20201:23 pmRNSHolding(s) in Company
21st Aug 202011:47 amRNSIssue of Equity
14th Aug 202010:48 amRNSPDS Announces Closing of $19m Offering
12th Aug 202012:28 pmRNSSofant secures £2.3m funding led by EMV Capital
12th Aug 20207:00 amRNSPDS Announces Pricing of $16.5m Common Stock Offer
11th Aug 202012:27 pmRNSPDS Announces Proposed Offering of Common Stock
7th Aug 20209:32 amRNSPosting of shareholder circular
6th Aug 20202:00 pmRNSHolding(s) in Company
5th Aug 202010:32 amRNSResult of Placing
5th Aug 20208:30 amRNSProposed acquisition and placing
4th Aug 202011:05 amRNSSecond Price Monitoring Extn
4th Aug 202011:00 amRNSPrice Monitoring Extension
27th Jul 20203:06 pmRNSPDS Announces Preclinical Data for PDS0203
14th Jul 20204:20 pmRNSPDS collaborator awarded grant for Versamune
29th Jun 20207:00 amRNSG–Tech Medical completes $6.7m Series A financing
25th Jun 20204:41 pmRNSSecond Price Monitoring Extn
25th Jun 20204:35 pmRNSPrice Monitoring Extension
24th Jun 20205:58 pmRNSHolding(s) in Company
24th Jun 20205:54 pmRNSHolding(s) in Company
24th Jun 20204:09 pmRNSResult of AGM
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
18th Jun 202011:05 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
18th Jun 20209:05 amRNSSecond Price Monitoring Extn
18th Jun 20209:00 amRNSPrice Monitoring Extension
18th Jun 20207:00 amRNSPDS & Farmacore Announce Co-Development-PDS0204
15th Jun 20202:41 pmRNSPDS Announces Initiation of Phase 2 Trial PDS0101
8th Jun 20204:42 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
5th Jun 20209:14 amRNSPDS Announces Trial of its Lead Product, PDS0101
1st Jun 20207:00 amRNSNotice of AGM
13th May 20202:46 pmRNSPDS Reports Results for Q1 2020 & Business Update
1st May 202011:33 amRNSConfirmation of Board Changes
30th Apr 202012:06 pmRNSPDS expands CRADA with National Cancer Institute
27th Apr 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.